[Treatment of non-cirrhotic, non-tumoural portal vein XXXX ].

@entity1 @entity390 @entity101 @entity63 @entity5 @entity384 @entity391 @entity490 @entity1575 @entity715
UNASSIGNED: @entity715 of the splenoportal axis not associated with @entity1575 or @entity5 is a rare disease whose prevalence ranges from 0.7 to 3.7 per 100,000 inhabitants. However, this entity is the second most common cause of portal @entity101 . Prothrombotic factors are present as an underlying cause in up to 70% of @entity1 and local factors in 10-50%. The coexistence of several etiological factors is frequent. Clinical presentation may be acute or chronic (portal cavernomatosis). The acute phase can present as @entity490 , @entity390 , @entity391 , fever, rectorrhagia, @entity384 , and @entity63 . In this phase, early initiation of anticoagulation is essential to achieve portal vein recanalization and thus improve @entity1 prognosis. In the chronic phase, symptoms are due to @entity101 . In this phase, the aim of treatment is to treat or prevent the complications of portal @entity101 . Anticoagulation is reserved to @entity1 with a proven underlying thrombophilic factor.
